elements
-live
Search elements, keywords, and sectors
🔎
Elements
Subjects
Pricing
Log in
Sign up
Home
/
Subjects
/
Castration
← Back to subjects
Current data, viewed at
Yearly
resolution.
Personal members see monthly resolution →
Keyword
keyword
Castration
RIS
0.001
(Research Intensity Score)
Papers
202
Top papers
Lutetium-177–PSMA-617 for Metastatic Castration-Resistant Prostate Cancer
2021 · 2750 citations
FDA Approval Summary: Lutetium Lu 177 Vipivotide Tetraxetan for Patients with Metastatic Castration-Resistant Prostate Cancer
2022 · 237 citations
Novel framework for treatment response evaluation using PSMA-PET/CT in patients with metastatic castration-resistant prostate cancer (RECIP 1.0): an international multicenter study
2022 · 136 citations
Randomized Phase II Study Evaluating the Addition of Pembrolizumab to Radium-223 in Metastatic Castration-resistant Prostate Cancer
2024 · 37 citations
Systemic Therapies for Metastatic Castration-Resistant Prostate Cancer: An Updated Review
2023 · 69 citations
PSMA targeted Therapy: From molecular mechanisms to clinical breakthroughs in castration-resistant prostate cancer
2025 · 16 citations
AR alterations inform circulating tumor DNA detection in metastatic castration resistant prostate cancer patients
2024 · 21 citations
Safety Analyses of the Phase 3 VISION Trial of [177Lu]Lu-PSMA-617 in Patients with Metastatic Castration-resistant Prostate Cancer
2024 · 33 citations
Association of Declining Prostate-specific Antigen Levels with Clinical Outcomes in Patients with Metastatic Castration-resistant Prostate Cancer Receiving [177Lu]Lu-PSMA-617 in the Phase 3 VISION Trial
2024 · 21 citations
Newest papers
Ractopamine under dietary protein adjustment improves growth performance and carcass traits of immunocastrated and surgically castrated pigs slaughtered 21 days after vaccination
2026
The influence of sex hormones on cardiac and skeletal muscle function in the MDX mouse model of Duchenne Muscular Dystrophy
2026
PSMA targeted Therapy: From molecular mechanisms to clinical breakthroughs in castration-resistant prostate cancer
2025 · 16 citations
Health-related quality of life, pain, and symptomatic skeletal events with [177Lu]Lu-PSMA-617 in patients with progressive metastatic castration-resistant prostate cancer (PSMAfore): an open-label, randomised, phase 3 trial
2025 · 13 citations
Lesion Absorbed Dose–Response Relationship in Patients with Metastatic Castration-Resistant Prostate Cancer Undergoing [ 177 Lu]Lu-PSMA-617 Radiopharmaceutical Therapy
2025 · 10 citations
Randomized Phase 2 Trial of an Extended and Flexible Dosing Schedule of 177 Lu-PSMA Molecular Radiotherapy in Patients with Metastatic Castration-Resistant Prostate Cancer (FLEX-MRT): Study Protocol
2025 · 7 citations
Treatment of metastatic castration-resistant prostate cancer: review of current evidence and synthesis of expert opinions on radioligand therapy
2025 · 10 citations
First real-world clinical experience with [177Lu]Lu-PSMA-I&T in patients with metastatic castration-resistant prostate cancer beyond VISION and TheraP criteria
2025 · 9 citations
Assessment of bone mineral density in men with de novo metastatic castration-sensitive prostate cancer treated with or without abiraterone acetate plus prednisone in the PEACE-1 phase 3 trial
2025 · 7 citations
Browse all papers →
Castration's history
Research intensity over time
Yearly
Personal members see monthly resolution →
Data temporarily unavailable — please try again shortly.
Close ✕
Castration's papers
Ordered by current research-activity contribution.
Loading…
Close ✕
Read full text ↗
Share
Share on X
Share on Facebook
Share on LinkedIn
Copy link